{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:03:10Z","timestamp":1792519390751,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lanwpc.2024.101096","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T16:51:31Z","timestamp":1716223891000},"page":"101096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase\u00a02 study"],"prefix":"10.1016","volume":"47","author":[{"given":"Min","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenxian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-E","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.lanwpc.2024.101096_bib1","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.lanwpc.2024.101096_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101096_bib3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.lanwpc.2024.101096_bib4","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.2021010968","article-title":"How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment","volume":"137","author":"Ghanima","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lanwpc.2024.101096_bib5","first-page":"617","article-title":"[Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]","volume":"41","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"12","key":"10.1016\/j.lanwpc.2024.101096_bib6","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101096_bib7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.lanwpc.2024.101096_bib8","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101096_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/09537104.2019.1624706","article-title":"The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis","volume":"30","author":"Li","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.lanwpc.2024.101096_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-019-00049-0","article-title":"Top drugs and companies by sales in 2018","author":"Urquhart","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.lanwpc.2024.101096_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12288-017-0885-x","article-title":"Infusion related hypersensitivity reactions with Bio-similar anti CD-20 monoclonal antibody rituximab in Indian patients: a retrospective study","volume":"34","author":"Prakash","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"11","key":"10.1016\/j.lanwpc.2024.101096_bib12","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.lanwpc.2024.101096_bib13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/annrheumdis-2017-211281","article-title":"A\u00a0randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101096_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2200848","article-title":"Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study","volume":"34","author":"Mageau","year":"2023","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.lanwpc.2024.101096_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.14782","article-title":"GPIIb\/IIIa autoantibody predicts better rituximab response in ITP","volume":"182","author":"Feng","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101096_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101096_bib17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.103291","article-title":"Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration","volume":"99","author":"Bussel","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.lanwpc.2024.101096_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ajh.24434","article-title":"Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia","volume":"91","author":"Chapin","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.lanwpc.2024.101096_bib19","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101096_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.lanwpc.2024.101096_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jcp.2009.068940","article-title":"Does rituximab aggravate pre-existing hypogammaglobulinaemia?","volume":"63","author":"Diwakar","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101096_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101096_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101096_bib24","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","article-title":"Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease","volume":"56","author":"Calabrese","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lanwpc.2024.101096_bib25","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101096_bib26","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/j.1756-185X.2011.01645.x","article-title":"Serum sickness and severe angioedema following rituximab therapy in RA","volume":"15","author":"Kumar","year":"2012","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.lanwpc.2024.101096_bib27","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.lanwpc.2024.101096_bib28","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia","volume":"118","author":"Audia","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101096_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101096_bib30","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses","volume":"2","author":"Baldo","year":"2013","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.lanwpc.2024.101096_bib31","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2013-03-491415","article-title":"Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia","volume":"122","author":"Audia","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lanwpc.2024.101096_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.14664","article-title":"The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia","volume":"178","author":"Arnold","year":"2017","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.lanwpc.2024.101096_bib33","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2016-11-751719","article-title":"Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients","volume":"129","author":"Porcelijn","year":"2017","journal-title":"Blood"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:34:55Z","timestamp":1719988495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606524000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"alternative-id":["S2666606524000907"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101096","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase\u00a02 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101096"}}